Tezcat Biosciences

Executive Summary

Tezcat Biosciences is a preclinical-stage biotech company based in Cambridge, MA, founded in 2021. The company has developed a novel, receptor-independent drug delivery platform that exploits macropinocytosis, a cellular process often upregulated in Ras-activated cancers. By targeting this mechanism, Tezcat aims to deliver protein-drug conjugates selectively to cancer cells, overcoming a key challenge in treating Ras-driven tumors, which are notoriously difficult to address with conventional therapies. The platform is designed to be disease- and payload-agnostic, with potential expansion into neurodegenerative, inflammatory, and infectious diseases beyond oncology. Despite being at an early stage, the company's innovative approach addresses a significant unmet need in precision drug delivery. Key milestones such as preclinical proof-of-concept data and advancement toward IND-enabling studies will be critical for validating the platform's potential. If successful, Tezcat could offer a transformative modality for delivering therapeutic payloads that are currently limited by poor selectivity or toxicity.

Upcoming Catalysts (preview)

• Q4 2026Presentation of in vivo efficacy data in Ras-mutant cancer models60% success
• Q3 2027Initiation of IND-enabling studies and Series A financing40% success
• TBDStrategic partnership for platform expansion into neurology or inflammation30% success